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Abstract Deletion mutagenesis studies have suggested that 
there are two domains within APP which bind heparan sulphate. 
These domains have been cloned and expressed in the yeast 
Pichia pastoris. Both recombinant proteins bound to heparin. 
One domain (APP316-447) was further characterised by binding 
studies with peptides encompassing this region. Peptides homol-
ogous to APP316-346 and APP416-447 were found to bind 
heparin. Circular dichroism studies show that APP416-447 
shifted towards an a-helical conformation in the presence of 
heparin. This study suggests that heparin-binding domains may 
lie within regions high in a-helical structure. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Alzheimer's disease (AD) is characterised by the presence of 
amyloid plaques in the brain. A major component of these 
plaques is Aß, a polypeptide derived from a larger 110-130 
kDa amyloid precursor protein (APP) [1-3]. The physiological 
role of APP is unclear. APP may play a role in neurite out-
growth [4-8]. APP has been shown to bind heparan sulphate 
proteoglycans (HSPGs), heparin and extracellular matrix 
macromolecules [8-12]. We have shown that the HSPGs gly-
pican and perlecan inhibit the ability of APP to stimulate 
neurite outgrowth suggesting that the binding of APP to 
HSPGs is functionally important [13]. 
Deletion mutagenesis studies suggest that APP contains two 
domains responsible for binding to heparan sulphate [14]. The 
cysteine-rich domain, (CRD), between residues 18 and 194 
includes a putative heparin-binding sequence HBD1 [8]. A 
putative oc-helix-rich domain (HRD) which lies between resi-
dues 311 and 493 [14] includes another heparin-binding se-
quence, HBD2 [10]. 
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Abbreviations: Aß, the amyloid protein obtained from APP cleavage; 
AD, Alzheimer's disease; APP, amyloid precursor protein; APPœ, the 
695 amino acid isoform of the amyloid precursor protein; HSPG(s), 
heparan sulphate proteoglycan(s); PMSF, phenylmethylsulfonyl fluo-
ride; EDTA, ethylenediaminetetraaceticacid disodium salt; SDS-
PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis 
The aim of the present study was to map regions of APP 
which bind heparin. To accomplish this, both CRD and HRD 
were cloned and expressed in the methylotrophic yeast Pichia 
pastoris, and the expressed proteins examined for heparin 
binding. To localise specific heparin-binding regions within 
HRD, peptides spanning residues 316-447 of APP695 were 
synthesised and analysed by heparin affinity chromatography 
and circular dichroism. Our studies show that the regions rich 
in secondary structure within APP are both capable of hep-
arin binding. 
2. Materials and methods 
2.1. Materials 
Econo-Pac heparin cartridges (5 ml) were from Bio-Rad (North 
Ryde, NSW, Australia). Amidated and acetylated peptides encom-
passing residues 316-346, 347-381, 382-412 and 413-447 of APPœ 
were commercially synthesised by Chiron-Mimotopes (Clayton, Vic-
toria, Australia). Peptides were purified by reversed-phase high per-
formance liquid chromatography on a 5 um Brownlee Spheri5 RP-18 
column (100x4.6 mm), using an Applied Biosystems 400 Solvent 
Delivery System as described by LePage et al. [15]. The pPIC-9 ex-
pression vector was purchased from Invitrogen (San Diego, CA) and 
the oligonucleotide primers from Life Technologies (Mulgrave, Victo-
ria, Australia). HiTrap chelating affinity columns were from AMRAD 
Pharmacia Biotech (Boronia, Victoria, Australia). Heparin (porcine 
intestinal mucosa), ethylenediaminetetraaceticacid disodium salt 
(EDTA) and phenylmethylsulfonyl fluoride (PMSF) were purchased 
from Sigma Chemical Co. (St. Louis, MO). The anti-FLAG-M2 
monoclonal antibody was from Eastman Kodak (New Haven, CT) 
and the anti-APP monoclonal antibody 22C11 was from Boehringer 
Mannheim (Germany). Goat anti-mouse immunoglobulins conjugated 
to alkaline phosphatase were from Promega Corporation (Madison, 
WI). The bicinchoninic acid (BCA) protein assay kit was from Pierce 
Biochemicals (Rockford, IL). 
2.2. Expression of recombinant CRD and HRD of human APP in 
P. pastoris 
2.2.1. Cysteine-rich domain (CRD). The cysteine-rich domain 
(CRD) from residues 18-194 was amplified from a vector containing 
the APP696 cDNA sequence [16] with primer 1 (5'-CCCCGGGATG-
CTGGAACCCACTGATGG-3') and primer 2 (5'-CCCCGGGCTA-
GTCACTTTCTTCAGCCAGTGGG-3'). The 551 base pair fragment 
was digested with Smal and cloned into the pPIC-9 vector digested 
with SnaBl. The expression vector was digested with Sgfll prior to 
transfection into P. pastoris (GS115) to allow for recombination of 
the expression cassette into the alcohol oxidase site [17]. Cultures were 
grown for 48 h and induced with 3% (v/v) methanol for 24 h as 
previously described [18]. Since the pPIC-9 vector directs secreted 
expression of the recombinant protein, cells were removed from the 
medium by centrifugation (lOOOOXg, 4°C, 30 min), the medium was 
passed through a 0.45 um filter and PMSF added to a final concen-
tration of 0.4 mM. The medium was then applied on to a 5 ml HiTrap 
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affinity column equilibrated with 0.02 M Na 2HP0 4 , 0.5 M NaCl, pH 
7.2 (start buffer) and charged with 0.1 M CUSO4. The column was 
washed with 25 ml start buffer and eluted with start buffer containing 
0.05 M EDTA. The eluate was then applied on to a Sephadex G-25 
(PD-10) column to desalt and exchange the buffer into 50 mM Tris-
HC1 pH 7.4. Yields of the recombinant protein were 24 mg purified 
protein/1. 
2.2.2. a-Helix-rich domain (HRD). The putative a-helix-rich do-
main (HRD) was amplified from APPßgs cDNA as described above 
with primer 1 (5'-CTCGAGGAA TTCGACTACAAGGACGACG-
ATGACAAGTTCCAGAAAGCCAAAGAG-3') and primer 2 (5'-
CAGGGAGAATTCTTAATTCATGCGCTCATAAATGACACG 
G-3'). Primer 1 also contained the eight-amino acid FLAG epitope 
(5'-GACTACAAGGAC GACGATGACAAG-3') for immunodetec-
tion of the recombinant protein. The PCR fragment was digested with 
EcoKl and cloned into EcoRl digested pPIC-9. The expression vector 
was digested as described above. Recombinant protein expression was 
induced for 5 days using 1% (v/v) methanol as previously described 
[19]. The medium was collected as described above and protease in-
hibitors added (0.4 mM PMSF, 1 ug/ml aprotinin, 1 |lg/ml pepstatin 
A, 2 mM EDTA, 5 uM E-64). The supernatant was diluted 50-fold 
for heparin-binding analysis. Yields of the recombinant protein were 
approximately 100 ug/l. 
2.3. SDS-polyacrylamide gel electrophoresis and Western blotting 
Aliquots of culture supernatant from P. pastoris were subjected to 
electrophoresis on 15% mini SDS-polyacrylamide gels [20]. Gels were 
electrophoresed at 40 mA each, proteins were transferred for 3 h at a 
current of 1 Amp onto nitrocellulose membranes. Membranes were 
blocked in 5% (w/v) skim milk powder in 20 mM Tris-HCl pH 7.4 
containing 0.15 M NaCl (TBS). CRD was detected with 22C11, a 
monoclonal antibody which recognises an epitope near the N-termi-
nus of APP. HRD was detected with the anti-FLAG-M2 monoclonal 
antibody. Membranes were rinsed in TBS, incubated with a secondary 
antibody conjugated to alkaline phosphatase and developed with Fast 
Red/Naphthol AS-MX substrate. 
2.4. Heparin affinity chromatography 
Recombinant protein (100 ug) or purified peptides (1 mg) were 
applied on to a 5 ml Econo-Pac heparin cartridge pre-equilibrated 
in 20 mM Tris-HCl pH 7.4 (Tris buffer) using a Bio-Rad Econo 
System. After an initial wash phase of 20 min with Tris buffer, the 
column was eluted with a linear gradient of 0-1 M NaCl at a flow rate 
of 1.0 ml/min over 60 min. Fractions of 1.0 ml were collected. To 
detect the recombinant proteins, 300 ul fractions were applied on to 
nitrocellulose membranes using a Bio-dot Microfiltration apparatus 
(Bio-Rad). Membranes were blocked in 5% (w/v) skim milk powder 
in TBS and detected with the appropriate monoclonal antibodies as 
described above. Images were digitised and staining intensity quanti-
fied by densitometry using the NIH Image software (VI.57, W. Ras-
band, NIH, Bethesda, MD). The amount of protein was determined 
using the BCA protein assay kit from Pierce with bovine serum albu-
min as a standard [21]. Eluted peptides were detected spectrophoto-
metrically by measuring the absorbance of each fraction at 214 nm. 
2.5. Circular dichroism 
Circular dichroism (CD) spectra were recorded at 20°C in a 1 mm 
cell using an AVIV 62 DS spectrometer with an electronic temper-
ature controlling device (Lakewood, NJ). Control CD spectra were 
generated for the 40 mM sodium phosphate buffer pH 7.4 and for 
heparin alone to correct for any background influence. The fraction of 
cc-helical content was calculated according to the method of Wu et al. 
[22] using the observed mean residue ellipticity at 222 nm and the 
method of Greenfield and Fasman [23] using the mean residue ellip-
ticity at 208 nm. 
3. Results 
3.1. Expression of CRD and HRD in P. pastoris 
Deletion mutagenesis studies by Clarris et al. [14] suggested 
that at least two regions in APP, the C R D between residues 
18-194 and a putative H R D between residues 311^493 may 
bind heparin. To confirm whether these regions contain hep-
Fig. 1. Analysis of the heparin-binding domains of APP expressed 
in P. pastoris. A: Western blot of HRD and CRD secreted into the 
culture medium. Culture medium from the pPIC-9 vector alone 
showed no immunoreactivity. HRD was detected with the anti-
FLAG monoclonal antibody. Three bands (13 kDa, 10 kDa and 34 
kDa) were observed on the Western blot. CRD was detected with 
the monoclonal antibody 22C11. A 20 kDa band was observed. B: 
Heparin affinity chromatography of CRD (•) and HRD (o). 100 
(xg of recombinant protein was applied on to a heparin-sepharose 
affinity column and eluted with a linear gradient of 0-1 M NaCl in 
20 mM Tris-HCl pH 7.4. CRD eluted at ~0.35 M NaCl and HRD 
between 0.4-0.7 M NaCl. Results are expressed as a percentage of 
the total immunoreactivity for each recombinant protein. 
arin-binding domains, both regions were cloned and expressed 
in P. pastoris. 
As the pPIC-9 expression vector directs extracellular expres-
sion of the recombinant protein, the culture supernatant was 
analysed by Western blotting. C R D was detected with the 
monoclonal antibody 22C11. A single 20 k D a band was ob-
served, corresponding to the calculated molecular mass of 
20.9 k D a (Fig. 1A). H R D was detected with an an t i -FLAG 
monoclonal antibody [24]. Two major bands migrating at 13 
k D a and 10 k D a were detected (Fig. IB), lower than expected 
from the predicted molecular mass of the recombinant protein 
(16.9 kDa) . A very faint band migrating at 34 k D a was also 
observed. As this band was approximately twice the size ex-
pected for the recombinant fragment, it may correspond to a 
dimeric form. 
3.2. Heparin affinity chromatography of CRD and HRD 
The ability of C R D and H R D to bind heparin was exam-
ined. The supernatant obtained from the P. pastoris cultures 
was diluted 1:10 with Tris buffer and applied to a heparin 
column. Aliquots of fractions eluting from the column were 
applied on to nitrocellulose membranes and immunoreactive 
proteins detected with 22C11 for C R D or the an t i -FLAG-M2 
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Fig. 2. Heparin affinity chromatography of peptides encompassing 
APP316-447. Each peptide (1 mg) was applied to a 5 ml heparin af-
finity column, and eluted with a linear gradient of NaCl from 0-1 
M. APP316-346 and APP416^147 bound strongly to the column, 
APP382-415 bound weakly, while APP347-381 did not bind. 
domain rich in 
basic residues 
O basic residues 
A acidic residues 
Fig. 4. Helical wheel representation of the orientation of residues in 
a putative cx-helical model of APP4\6-M7. Basic amino acid resi-
dues predominantly segregate to one side of the helix, which may 
favour heparin binding. 
monoclonal antibody for HRD. Both recombinant proteins 
bound to the column. The CRD protein eluted off the column 
as a sharp peak at ~0.35 M NaCl (Fig. IB). The HRD 
protein eluted off the column in a broad peak between 0.4 
and 0.7 M NaCl (Fig. IB). 
3.3. Heparin affinity chromatography of peptides encompassing 
APP316-447 
To examine the heparin binding of specific regions within 
HRD further, four peptides of similar length homologous to 
APP316-346, APP347-381, APP382-415 and APP416-447 of 
APP695 were synthesised. To assess the ability of these pep-
tides to bind heparin, 1 mg of each peptide was applied to the 
heparin affinity column and eluted with a linear gradient of 
NaCl from 0-1 M. Fractions (1.0 ml) were collected and the 
absorbance measured spectrophotometrically at 214 nm (Fig. 
2). APP316-346 and APP416-447 bound strongly to the col-
umn, eluting at 0.38 M and 0.34 M NaCl respectively. 
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Fig. 3. CD spectra of peptides encompassing APP316-447. Each 
peptide (1 mg) was subjected to CD in the absence (—) or presence 
( ) of 150 ug/ml heparin. APP316-346 exhibited a spectrum rep-
resentative of an oe-helix both with and without heparin. APP347-
381 and APP382-415 were representative of random coil. APP416-
447 was random in the absence of heparin, but underwent a confor-
mational change to more a-helical character when heparin was 
added. 
APP382^U5 eluted at 0.27 M NaCl while APP347-381 did 
not bind. 
3.4. Circular dichroism 
To study the peptide-heparin interactions further, each pep-
tide was analysed by circular dichroism spectroscopy in the 
presence or absence of heparin (Fig. 3). The CD spectrum for 
APP316-346 in the absence (—) of heparin showed a-helical 
characteristics, represented by the double minima at 208 nm 
and 222 nm and a maximum at ~ 190 nm. The percentage of 
ce-helix was calculated to be 33% by the method of Wu et al. 
[22] and 36% by the Greenfield and Fasman method [23]. In 
the presence of 150 |xg/ml heparin the relative a-helical con-
tent increased by 24%> as calculated by the method of Wu et 
al. [22] and by 17% by the method of Greenfield and Fasman 
[23]. APP347-381 and APP382^H5 both demonstrated ran-
dom coil characteristics with a single large negative peak at 
199-200 nm and a very weak peak at 220 nm both in the 
absence and presence of heparin. In the absence of heparin, 
APP416-447 demonstrated characteristics of a random coil 
form. In the presence of heparin, the relative a-helical content 
increased by 26%, evident by an increase in mean residue 
ellipticity at 208 nm and 222 nm. 
4. Discussion 
Deletion mutagenesis studies suggest that there may be two 
regions within APP which bind heparin [14]. Both these do-
mains, the CRD (APP18-194), and a putative HRD 
(APP311-493) have also been predicted to be rich in secon-
dary structure [8,14]. In the present study, these domains were 
cloned and expressed in P. pastoris and found to bind hepa-
rin. 
Western blotting analysis demonstrated that the CRD ex-
pressed in P. pastoris had a molecular mass of 20 kDa, which 
agrees with the calculated molecular mass. The 13 kDa prod-
uct observed for the HRD would be the expected recombinant 
fragment, possibly C-terminally truncated (either intracellu-
larly or during secretion). The 10 kDa product may be due 
to further C-terminal proteolysis. Proteolytic degradation in 
the P. pastoris expression system can occur and has been 
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documented [18]. The identity of the recombinant protein was 
confirmed by the observation that the anti-FLAG antibody 
still detected the 13 kDa and 10 kDa products but no immu-
noreactivity was detected in the untransfected culture super-
natant. 
Four peptides encompassing HRD were synthesised and 
used to further characterise the heparin-binding capability 
and structural conformation of specific regions within this 
domain. The entire region between residues 316-447 contains 
a high concentration of basic amino acids. The peptides 
APP316-346, APP382^U5 and APP416-447 all bound to 
heparin, while APP347-381 did not bind. The fact that 
APP347-381 had a concentration of basic amino acids similar 
to the other peptides on either side of this region, suggested 
that a high concentration of basic amino acids alone may be 
insufficient to predict heparin binding. APP316-346 and 
APP382^U5 had a net charge of +3, APP416^147 had a net 
charge of +11, and APP347-381 had a net negative charge of 
— 1. Thus, the overall net charge on these peptides correlated 
with their heparin-binding capability. However, the binding of 
ligands to heparin is unlikely to involve solely a simple elec-
trostatic interaction, but is more likely to involve a specific 
conformational structure as well. 
CD studies showed that APP316-346 has a-helical charac-
teristics both in the absence and presence of heparin. 
APP416^-47 underwent a conformational change from ran-
dom coil to oc-helix in the presence of heparin, demonstrated 
by the double minima at 208 nm and 222 nm. The CD spec-
trum for APP347-381 and APP382-415 suggested that both 
these peptides adopt a random conformation in solution. 
APP382^U5 bound to heparin, although with a lower affinity 
than APP316-346 and APP415^147. Heparin binding of this 
peptide may fail to provide electrostatic stabilisation of the 
peptide which could favour formation of oc-helix. 
Our previous studies [14] predicted that the region of APP 
between residues 316 and 447 is predominantly a-helix. Our 
current studies with peptides further defines which regions 
within this domain may be involved in heparin binding due 
to their secondary structure. Since APP416-447 demonstrated 
a clear shift from random form to a-helix in the presence of 
heparin, a helical wheel representation of this peptide was 
constructed (Fig. 4). In this model, basic residues were found 
to segregate on one side of the helical surface. Helical wheel 
determination of the other peptides did not show this segre-
gation of basic residues. a-Helix may thus provide a good 
structure for binding heparin as it presents a rigid linear array 
of residues in which spacing of the residues may be appropri-
ate for binding of the negative charges in heparin. 
The binding of many proteins to heparin is often through 
regions containing a-helix [25,26]. Proteins such as acidic and 
basic fibroblast growth factor are induced to adopt a higher 
degree of a-helical structure upon binding to heparin [27,28]. 
APP peptides which did not have demonstrable secondary 
structure did not bind heparin. Several other studies have 
shown that heparin-binding domains are often associated 
with regions rich in secondary and tertiary structure 
[25,26,29]. 
The significance of heparin-binding domains for APP is still 
unclear. APP may play a role in neurite outgrowth, possibly 
through an interaction with HSPGs on the cell surface [13,30]. 
The RERMS sequence present within APP316^147 may be 
associated with the promotion of neurite outgrowth [7] 
although recent studies [30] suggest that the effect of this 
sequence on neurite outgrowth is not modulated via an 
HSPG. The N-terminal heparin-binding region may be in-
volved in the trophic function of APP [8]. A better under-
standing of the heparin-binding interactions of APP will 
shed more light on the function of APP and its role in AD 
pathogenesis. 
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